Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm trial of pemetrexed + cisplatin + bevacizumab induction followed by pemetrexed + bevacizumab maintenance in first-line nonsquamous advanced NSCLC
2008-006732-35Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, cisplatin and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: progression-free survival. Started Jun 2009; status: completed.
02
Drugs
pemetrexedcisplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006732-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006732-35.